Brokerages Set Replimune Group, Inc. (NASDAQ:REPL) Target Price at $9.75

Replimune Group, Inc. (NASDAQ:REPL) has been given an average recommendation of “Moderate Buy” by the eleven brokerages that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $9.75.

Several analysts recently weighed in on REPL shares. Wedbush upgraded shares of Replimune Group from a “neutral” rating to an “outperform” rating and lifted their target price for the company from $4.00 to $18.00 in a report on Monday, October 20th. HC Wainwright upgraded Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 price objective on the stock in a report on Monday, October 27th. Piper Sandler raised Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 target price on the stock in a research note on Monday, October 20th. Leerink Partnrs raised Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. Finally, JPMorgan Chase & Co. raised shares of Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 price target on the stock in a research report on Monday, October 20th.

Insider Buying and Selling at Replimune Group

In other Replimune Group news, Director Kapil Dhingra sold 3,169 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $10.40, for a total transaction of $32,957.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Konstantinos Xynos sold 7,248 shares of the stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $9.10, for a total transaction of $65,956.80. Following the completion of the sale, the insider directly owned 139,685 shares in the company, valued at approximately $1,271,133.50. This represents a 4.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 25,625 shares of company stock worth $257,607. 5.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Replimune Group

Large investors have recently bought and sold shares of the business. Tudor Investment Corp ET AL purchased a new stake in Replimune Group during the 3rd quarter worth about $87,000. Scientech Research LLC purchased a new stake in Replimune Group during the third quarter worth approximately $102,000. Fcpm Iii Services B.V. boosted its holdings in Replimune Group by 6.4% in the third quarter. Fcpm Iii Services B.V. now owns 4,158,368 shares of the company’s stock valued at $17,424,000 after purchasing an additional 248,672 shares in the last quarter. Braidwell LP boosted its holdings in Replimune Group by 550.3% in the third quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock valued at $11,523,000 after purchasing an additional 2,327,205 shares in the last quarter. Finally, Alliancebernstein L.P. increased its stake in Replimune Group by 23.4% in the third quarter. Alliancebernstein L.P. now owns 63,540 shares of the company’s stock valued at $266,000 after purchasing an additional 12,050 shares during the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Stock Up 2.0%

Shares of REPL opened at $9.88 on Wednesday. The company’s 50-day moving average price is $8.97 and its 200 day moving average price is $7.65. Replimune Group has a 12-month low of $2.68 and a 12-month high of $14.80. The company has a current ratio of 6.31, a quick ratio of 6.31 and a debt-to-equity ratio of 0.26. The firm has a market cap of $774.99 million, a P/E ratio of -2.86 and a beta of 0.66.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03). On average, sell-side analysts forecast that Replimune Group will post -2.97 earnings per share for the current year.

Replimune Group Company Profile

Replimune Group, Inc is a clinical?stage biotechnology company focused on developing next?generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.